ANTIGENICS INC. SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 11th, 2008 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is made and entered into as of January 9, 2008, by and among Antigenics Inc., a Delaware corporation (the “Company”) and the investors identified on Schedule I attached hereto (each, a “Purchaser”, and collectively, the “Purchasers”).
ANTIGENICS INC WARRANTAntigenics Inc /De/ • January 11th, 2008 • Biological products, (no disgnostic substances)
Antigenics Inc., a Delaware corporation (the “Company”), hereby certifies that, for value received, or its registered assigns (including permitted transferees, the “Holder”), as registered owner of this warrant (the “Warrant”), is entitled to purchase from the Company up to a total of shares (as adjusted from time to time as provided in Section 9) of Common Stock (as defined below), at an exercise price equal to $3.00 per share (as adjusted from time to time as provided in Section 9, the “Exercise Price”), at any time and from time to time from and after July 9, 2008 (the “Initial Exercise Date”) to and including January 9, 2018 (the “Expiration Date”), and subject to the following terms and conditions.
ANTIGENICS INC UNIT WARRANTAntigenics Inc /De/ • January 11th, 2008 • Biological products, (no disgnostic substances)
Antigenics Inc., a Delaware corporation (the “Company”), hereby certifies that, for value received, or its registered assigns (including permitted transferees, the “Holder”), as registered owner of this warrant (the “Warrant”), is entitled to purchase from the Company up to a total of units (each a “Unit”), each Unit (as adjusted from time to time as provided in Section 9) to consist of (i) one share (a “Warrant Share”) of Common Stock (as defined below) and (ii) one warrant (a “Share Warrant”), exercisable for ten years from the date of exercise of this Warrant, to purchase one share of Common Stock (a “Second Warrant Share”) at $3.00 per share in the form attached here to as Exhibit A, at an exercise price equal to $3.00 per share (as adjusted from time to time as provided in Section 9, the “Exercise Price”), at any time and from time to time from and after July 9, 2008 (the “Initial Exercise Date”) to and including January 9, 2010 (the “Expiration Date”), and subject to the followin
